We have a diversified and balanced clinical development pipeline that covers multiple therapeutic areas, including CNS, cardiovascular and immunological disorders, as well as orphan diseases.

Compound Mechanism of Action Target Indication Status More information
         
Daridorexant Dual orexin receptor antagonist Insomnia

Available as QUVIVIQ™ in the US, approved in the EU, under review in Switzerland and
Canada

Investor webcast
Aprocitentan*  Dual endothelin receptor antagonist Resistant hypertension management Phase 3 successful Investor webcast
Clazosentan Endothelin receptor antagonist Cerebral vasospasm assoc.
with aneurysmal subarachnoid hemorrhage

Commercially available as PIVLAZ™ in Japan

Global Phase 3

 Investor webcast
Lucerastat Glucosylceramide synthase inhibitor Fabry disease

Phase 3 – primary endpoint not met

Open Label Extension study (OLE) ongoing

  
Selatogrel P2Y12 receptor antagonist Suspected acute myocardial infarction Phase 3 Investor webcast
Cenerimod S1P1 receptor modulator Systemic lupus erythematosus Phase 3 in preparation  
ACT-539313 Selective orexin 1 receptor antagonist Under evaluation -  
Sinbaglustat
 GBA2/GCS inhibitor Rare lysosomal storage disorders Phase 1 complete  
ACT-1004-1239 CXCR7 antagonist Immunology  Phase 1 complete  
ACT-1014-6470 - Immunology Phase 1  
ACT-777991 - Immunology Phase 1  


* In collaboration with Janssen Biotech to jointly develop aprocitentan, Janssen Biotech has sole commercialization rights worldwide

Neurocrine Biosciences has a global license to develop and commercialize ACT-709478 (NBI-827104), Idorsia's novel T-type calcium channel blocker. ACT-709478 is currently investigated in two Phase 2 studies for the treatment of a rare form of pediatric epilepsy and essential tremor.

 

"I enjoy working for Idorsia because it has the culture of "let's do it" instead of "it's impossible"."

Application Manager, Corporate IT